Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Is Eyelid Laxity More Predictive for Identifying Patients with Obstructive Sleep Apnea (OSA) than the STOP-BANG Questionnaire?
Author Affiliations & Notes
  • Xhulio Arolli
    Ophthalmology, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, United States
  • Sarah Godel
    Northeast Ohio Medical University, Rootstown, Ohio, United States
  • Damla Oncel
    Ophthalmology, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, United States
  • Abhishek Ramini
    Ophthalmology, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, United States
  • Charles Bouchard
    Ophthalmology, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, United States
  • Footnotes
    Commercial Relationships   Xhulio Arolli None; Sarah Godel None; Damla Oncel None; Abhishek Ramini None; Charles Bouchard None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 6019. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Xhulio Arolli, Sarah Godel, Damla Oncel, Abhishek Ramini, Charles Bouchard; Is Eyelid Laxity More Predictive for Identifying Patients with Obstructive Sleep Apnea (OSA) than the STOP-BANG Questionnaire?. Invest. Ophthalmol. Vis. Sci. 2024;65(7):6019.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : OSA is a significant risk factor for biomechanical anterior segment and neurovascular posterior segment eye disease. Lax eyelid condition (LEC), diagnosed by abnormal elasticity of the eyelid, is associated with OSA. 5.9 million U.S. adults are diagnosed with OSA, costing healthcare $65-$165 B. 23.5 million people with undiagnosed OSA have an annual cost of $150 B. Strategies to identify biomarkers to uncover this overlooked disease with widespread ocular comorbidities, in addition to body mass index (BMI), family history, and snoring is an important public health issue and the aim of our study.

Methods : 150 patients with LEC were identified in the Loyola ophthalmology service from 12-2020 to 8-2023. The STOP-BANG questionnaire was completed for each patient and a home polysomnography (PSM) was obtained. Demographic information, BMI, and family history of OSA and/or snoring were documented.

Results : 150 patients with LEC had a home PSM testing. 37.3% of the patients were males and 62.7% females. Most (84.7%) patients with LEC were 51 to 80 years old. 62.7% of patients were Caucasian, 16% were Hispanic, 12% were African American, 4% were Asian, and 5.3% other. 44% of the 150 patients had a BMI >30, 32.7% had a BMI=30-25, 22% had a BMI=25-18.5, and 0.07% had a BMI <18.5. A family history of snoring was present in 99.93% of patients, with most patients (43%) having a father who snored. 117 of the patients with LEC (78%) had OSA of which 16.2% was severe, 32.5% was moderate, and 48.7% was mild. 48/117 (41%) patients with OSA had a BMI<30, of which 61% had mild, 31.1% had moderate, and 8.2% had severe OSA. 69/117 (59%) with BMI ≥30, 38% had mild, 36% had moderate, and 27% had severe OSA. We correlated OSA severity with the STOP-BANG score. Patients without OSA (AHI <5) had a mean score of 3.42, patients with mild OSA (AHI 5-15) had a score of 3.31, moderate OSA (AHI 15-30) had a score of 4.05, and patients with severe OSA (AHI >30) had a score of 4.95.

Conclusions : LEC is an important risk factor for OSA, predicting OSA in 78% of patients. 41% of patients with OSA determined from home PSM had a BMI <30, suggesting that BMI should not be used as the sole risk factor for OSA. The public health and ocular disease impact of undiagnosed OSA must be addressed. Clinical training to diagnose LEC may offer a practical and effective strategy to identify patients at risk for OSA.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×